Document Detail


Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
MedLine Citation:
PMID:  18353996     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on ambulatory blood pressure was assessed in nondiabetic patients with mild to moderate hypertension in a randomized, double-blind, placebo-controlled, 3-period crossover study. Nineteen patients on stable treatment with antihypertensive agent(s) received sitagliptin 100 mg b.i.d., 50 mg b.i.d., or placebo for 5 days, with at least a 7-day washout interval between periods. Twenty-four-hour ambulatory blood pressure, including systolic blood pressure, diastolic blood pressure, and mean arterial pressure, were monitored on days 1 and 5. Relative to placebo on day 1, the mean difference in 24-hour systolic blood pressure was -0.9 mm Hg (90% confidence interval: -2.9 to 1.1; P = .46) with sitagliptin 50 mg b.i.d. and -2.8 mm Hg (90% confidence interval: -4.9 to -0.8; P < .05) with 100 mg b.i.d. On day 5, the mean difference in 24-hour systolic blood pressure was -2.0 mm Hg (90% confidence interval: -3.5 to -0.4; P < .05) with 50 mg b.i.d. and -2.2 mm Hg (90% confidence interval: -3.7 to -0.6; P < .05) with 100 mg b.i.d. relative to placebo. For 24-hour diastolic blood pressure, there were no between-group differences in mean 24-hour diastolic blood pressure on day 1. On day 5, sitagliptin 50 mg and 100 mg b.i.d significantly (P < .05) lowered mean 24-hour diastolic blood pressure by -1.8 mm Hg (90% confidence interval: -2.8 to -0.8) and -1.6 mm Hg (90% confidence interval: -2.6 to -0.7), respectively, relative to placebo. Sitagliptin produced small but statistically significant reductions of 2 mm Hg to 3 mm Hg in 24-hour ambulatory blood pressure measurements acutely (day 1) and at steady state (day 5), and was generally well tolerated in nondiabetic patients with mild to moderate hypertension.
Authors:
Goutam C Mistry; Andrea L Maes; Kenneth C Lasseter; Michael J Davies; Keith M Gottesdiener; John A Wagner; Gary A Herman
Related Documents :
19606236 - Health-related quality of life and blood pressure control in hypertensive patients with...
951896 - The hypertension of long-term hemodialysis patients: studies with an angiotensin ii ant...
6703816 - Military antishock trousers. effect on hemodialysis-induced hypotension.
2715066 - The influence of initial hemoglobin and blood pressure levels on results of radiation t...
17885326 - Effect of repeated induced airway collapse during total liquid ventilation.
8797666 - Acute hypertension, but not thrombolysis, increases the incidence and severity of hemor...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-03-19
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  48     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-28     Completed Date:  2008-08-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  592-8     Citation Subset:  IM    
Affiliation:
Merck Research Laboratories, RY34-A400, 126 East Lincoln Avenue, Rahway, NJ 07065, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adolescent
Adult
Aged
Antihypertensive Agents / administration & dosage,  therapeutic use*
Blood Pressure / drug effects*
Blood Pressure Monitoring, Ambulatory
Cross-Over Studies
Dipeptidyl-Peptidase IV Inhibitors / administration & dosage,  pharmacology,  therapeutic use
Double-Blind Method
Female
Humans
Hypertension / drug therapy*,  physiopathology
Male
Middle Aged
Pyrazines / administration & dosage,  therapeutic use*
Treatment Outcome
Triazoles / administration & dosage,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Dipeptidyl-Peptidase IV Inhibitors; 0/Pyrazines; 0/Triazoles; 0/sitagliptin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation pr...
Next Document:  Quantitative performance of E-Scribe warehouse in detecting quality issues with digital annotated EC...